Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Interest & Investment Income (2021 - 2022)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Interest & Investment Income for 2 consecutive years, with $322000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Interest & Investment Income rose 6340.0% year-over-year to $322000.0, compared with a TTM value of $536000.0 through Sep 2022, changed N/A, and an annual FY2021 reading of $97000.0, down 91.45% over the prior year.
  • Interest & Investment Income was $322000.0 for Q3 2022 at Kiniksa Pharmaceuticals International, up from $103000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $322000.0 in Q3 2022 and bottomed at $5000.0 in Q3 2021.